Jayamas Medica Industri TBK PT

Jayamas Medica Industri TBK PT maintains a strong liquidity position, with a current ratio of 10.36 and cash and equivalents amounting to 541.8 billion IDR. The company's debt-to-equity ratio is 0.08, indicating a conservative capital structure with minimal leverage. Free cash flow of 235.3 billion IDR supports operational flexibility and potential reinvestment. Profitability metrics show a return on equity of 13.49% and a return on assets of 11.47%, both exceeding the industry median for medical equipment and supplies firms. Operating income of 409.4 billion IDR and net income of 366.9 billion IDR reflect strong margins, supported by a gross profit of 713.9 billion IDR. The company's revenue is concentrated in its core medical equipment and supplies business, with no disclosed geographic diversification beyond Indonesia. This concentration may expose the company to regional economic and regulatory risks. Growth trajectory is supported by a robust operating cash flow of 395.1 billion IDR and capital expenditures of -108.1 billion IDR, indicating ongoing investment in infrastructure and production capacity. Analysts have assigned a mean price target of 220.00 IDR, with a single "buy" recommendation and no "strong buy" or "hold" ratings. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and high cash reserves mitigate financial distress risk. No dilution pressure is currently evident, with basic and diluted shares outstanding aligned at 27.0 billion shares. Recent events include consistent financial performance and no material adverse disclosures in the latest filings. The company's capital structure and operational metrics suggest a stable and well-managed business.